UCB (OTCMKTS:UCBJF) Shares Gap Down - Here's Why

Key Points

• UCB SA's stock price experienced a significant drop, opening at $283.31 after closing at $302.16, indicating a substantial market shift before the trading session.
• Analysts have maintained positive outlooks for UCB, with Deutsche Bank and Morgan Stanley restating their "buy" and "overweight" ratings, respectively, contributing to the stock's average rating of "Buy."
• UCB SA specializes in biopharmaceuticals for neurology and immunology, with key products aimed at treating various inflammatory diseases, epilepsy, and allergies.

UCB SA (OTCMKTS:UCBJF - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $302.16, but opened at $283.31. UCB shares last traded at $283.31, with a volume of 4 shares traded.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of UCB in a research note on Monday, October 6th. Morgan Stanley restated an "overweight" rating on shares of UCB in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB has an average rating of "Buy".

UCB Price Performance

The company has a 50-day moving average price of $254.25 and a two-hundred day moving average price of $206.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.